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Background:Nivolumab is an anti-programmed death 1 (PD-1) monoclonal anti-
body, which has demonstrated antitumor efficacy in clinical trials of various malignant
tumors. Pneumonitis is a common adverse event in patients treated with nivolumab.
However, the difference of the frequency and severity of nivolumab-induced pneumo-
nitis across different tumor types is not clear.
Methods:We retrospectively reviewed 311 patients who were diagnosed as non-small
cell lung cancer (NSCLC), head and neck cancer (HNC), or gastric cancer (GC), and
treated with nivolumab at Aichi Cancer Center Hospital, Japan, between December,
2015 and April, 2018. Patients who underwent chest computed tomography (CT) right
before starting of nivolumab and have not received chemotherapy after the last chest
CT were included in the analysis. Patients who previously received thoracic radiother-
apy were excluded from the analysis. Pulmonary fibrosis score (scores 0–5) on baseline
chest CT was assessed by two independent radiologists.
Results: 196 patients were included in the analysis, and 96 patients were NSCLC, 50
patients were HNC, and 50 patients were GC, respectively. Pulmonary fibrosis score1
was found in 27.1% in NSCLC, 10.0% in HNC, and 12.0% in GC (p¼ 0.02). Twenty-
two patients (11.2%) experienced nivolumab-induced pneumonitis, of which three
(1.5%) were grade3. The median onset time of pneumonitis after starting nivolumab
was 61 days (range, 2–634 days). According to the analysis of tumor types, the rates of
pneumonitis were 14.6% in NSCLC, 10.0% in HNC, and 6.0% in GC, respectively.
There were no significant differences in the incidences of pneumonitis between three
tumor types. Univariate andmultivariate logistic regression analysis revealed that male
and pulmonary fibrosis score1 significantly increased the risk of developing nivolu-
mab-induced pneumonitis.
Conclusions: Pulmonary fibrosis was foundmore frequently in NSCLC than HNC and
GC. Our results indicated that male and pulmonary fibrosis are the risk factors for nivo-
lumab-induced pneumonitis.
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Background: RETwas mapped to chromosome (Chr) 10q11.2 and encodes a trans-
membrane receptor expressedmainly on derived neural crest and urogenital cells. RET
plays a key role in the maturation of different peripheral nervous system cell lineages, in
kidneymorphogenesis, and in spermatogenesis. The aim of this study was to investigate
the clinical value of RET rearrangement in NSCLC cell blocks from pleural effusion.
Methods: 215 cases of RET rearrangement non-small cell lung cancer (NSCLC) cell
blocks from pleural effusion, and 404 cases of tissues were detected by the reverse tran-
scription polymerase chain reaction (RT-PCR)method. The consistency of RET rear-
rangement was examined in 74 cases of patients with tissue and cell blocks.
Results: RET rearrangement was found in 4 of 215 cell blocks (positive detection rate of
1.86%). RET rearrangement was detected in 5 of 404 tissue blocks (positive detection
rate of 1.24%). There were 73 cases of the 74 (98.65%) cases which showed the same
consistency of RET rearrangement in the cell and tissue blocks. RET rearrangement was
detected in 1 of 74 (1.35%) cell blocks, and 2 of 74 (2.70%) tissue blocks.
Conclusions: The rate of RET rearrangement in cell blocks of NSCLC is higher than in
matched tissue blocks. The patients with malignant pleural effusion are likely to tend to
RET rearrangement.
Legal entity responsible for the study:Chun-Wei Xu.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background:Mismatch repair deficient (dMMR) cancers harbour high levels of micro-
satellite instability and somatic mutations. Pembrolizumab was the 1st tumour site
agnostic approval in dMMR cancers that showed durable objective responses. The aim
of this study was to determineMMR deficiency by easily available immunohistochem-
istry (IHC) testing in metastatic solid tumours that have progressed on prior therapies
and have no alternative options, to identify candidates for PD-1 blockade therapy in an
Indian setup.
Methods: A prospective analysis was done betweenMay 2017 to April 2018 of 102
patients with metastatic colorectal (mCRC) and non-colorectal (gastric, hepatobiliary,
pancreatic, small bowel, endometrial and breast) cancers that failed on standard thera-
pies. Mismatch repair protein loss was determined by IHC on paraffin blocks of
tumour tissue.
Results: 102 patients were evaluated of which 66 patients hadmCRC. 36 patients had
metastatic non-colorectal cancer of which most common tumour type was gastric can-
cer (26 patients) followed by hepatobiliary (5 patients), endometrial (2 patients), and
pancreatic, small bowel and breast cancer (1 patient each). A total of 12 patients
(11.8%) wereMMR deficient. 6 patients (9%) of mCRC, 4 patients (15.4%) of gastric
cancer, 1 patient of hepatobiliary cancer and 1 patient of endometrial cancer showed
MMR deficiency.
Conclusions: This study demonstrated that 11.8% patients in an unselected population
haveMMR deficiency. These patients are ideal candidates to whom immunotherapy
can be offered as an option after progression on standard therapies. There is no other
study from India highlighting frequency of dMMR inmultiple tumour types with
metastatic disease. MMR testing has a growing application in cancer therapeutics –
lynch diagnosis, prognostication, predictor of chemotherapeutic efficacy in stage 2
CRC and anti PD-1 efficacy in metastatic cancers. IHC testing forMMR is a widely
available and economical screening tool with fast turnaround time, yet it is still an
underutilisedmodality in India. Hence the present study was undertaken to highlight
its importance in management of metastatic cancers in present era of precision
medicine.
Legal entity responsible for the study: Ethics Committee, Manipal Hospital.
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Background:Nowadays many researchers are focused on a study of genes involved in
the repair of double-strand breaks (DSB) by homologous recombination (HR) to iden-
tify new predictive markers of cancer therapy. Patients with triple negative breast cancer
(TNBC) without mutations of BRCA genes (BRCAmut), which are the well-known
markers of HR deficiency and targets for DNA-damaging therapy, have a heterogene-
ous response to treatment and as a result high mortality rate. Therefore, the aim of this
study was to evaluate aMre11-NBN-RAD50 complex which plays a key role in DSB
repair as a potential predictive marker of HR deficiency among TNBC patients.
Methods: In silico analysis of theMre11, RAD50 and NBN gene copy number altera-
tions (CNAs) was performed utilizing the genomic profiles and clinical data of 2509
breast cancers (METABRIC, Nature 2012 &Nat Commun 2016 studies). Alterations
(mutations, deep deletions (del) and amplifications (ampl)) of 41 key genes involved in
DSB pathways and/or tumorigenesis excluding patients with BRCA1/2 alterations were
used to separate a TNBC patients cohort (n¼ 399) into groups: with conditionally
“breached HR" (n¼ 157) and with "normal HR"(n¼ 242), For this a median altera-
tions amount across the patients was used as a threshold. Statistical analysis (chi-
squared test, logistic regression, ROC curve) was performed using RStudio.
Results: The NBN gains and ampl occurred in 41,9%, RAD50 del – in 38,1%,MRE11
del - 21,8% of TNBC patients. TNBC patients with “breached HR" had higher fre-
quency (p-value< 0,01) of RAD50 (64,5%) andMRE11 (34,4%) del, as well as NBN
(72%) ampl and gains than patients with "normal HR" (20,7%,13,6% and 22,3% corre-
spondingly). Based on the above-mentioned CNAs the model for prediction of HR
deficiencies with – 60,5%, sensitivity and 84,3% specificity (area under the ROC curve
– 0,85) was created.
Conclusions: ThusMre11-NBN-RAD50 complex could be considered as potential HR
deficiency marker in tumors of TNBC patients which could predict response to DNA
damaging therapy. Model will be cross-validated and optimized in future.
Legal entity responsible for the study: Research Laboratory "Biomarker".
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Background: Papillary thyroid carcinoma (PTC) is the most common histological thy-
roid cancer, accounting for approximately 80% of thyroid cancers. BRAF V600Emuta-
tions are the most common genetic mutation in PTC and the relationship between
BRAF V600Emutations and PTC has recently been a focus of research. While the
genetic landscape of BRAF V600E wild PTC patients is unclear. The aim of this study is
to investigate the genetic landscape of PTC without BRAF V600E.
Methods: A total of 120 patients with PTC were recruited between 2011 and December
2014. The status of BRAF V600E was detected by reverse transcription polymerase
chain reaction (RT-PCR). The BRAF V600E wild patients were validated by next gener-
ation sequencing (NGS).
Results: In this study, 14 patients were identified without BRAF V600E (11.67%, 14/
120). The BRAF V600E wild type patients were similar to the mutant patients, and
could not be distinguished bymorphologic features. 57.14% patients (8/14) were found
with gene mutation by NGS, including BRAFW604*þ P57L plus TSHR V448I (1
patient); EIF1AX S74L (1 patient); PIK3CA S405FþR693H plus R908K (1 patient);
CCDC6-RET (2 patients); RET-PDE5A (1 patient); PIK3CA S405F plus PTEN R233*
plus RET E623K (1 patient); KRAS Q61K (1 patient).
Conclusions: BRAF V600E wild PTC patients more frequently show RET fusion.
MTOR activation is also a commonmechanism for the BRAF wild PTC. The detection
of RET fusion gene is beneficial to the diagnosis for the atypical BRAF V600E wild PTC.
Legal entity responsible for the study:Mei-yu Fang.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background: Anaplastic Lymphoma Kinase (ALK) and C-Ros Oncogene 1 (ROS1)
fusion testing plays an important role in precision medicine with ALK and ROS1 tyro-
sine kinase inhibitors (TKIs). However, the currently available methods such as FISH
and PCR based assays are time-consuming and expensive. The purpose of this study
was to detect ALK and ROS1 fusion proteins in lung cancer cell lines and tumor sam-
ples with non-small cell lung cancer (NSCLC), using the microfluidic immunoassay
device which we had already developed for the detection of EGFRmutation.
Methods: The diagnostic device consisted of capture antibody (specific antibody
against ALK or ROS1) and photo-reactive polymer. The antibody-immobilized poly-
mer wall (40lmwidth, 40 lmheight, and 4mm length) was constructed at the center
of a microchannel (1mmwidth, 40 lmheight, and 8.5mm length) by ultraviolet light
irradiation. By using the device, the sandwich-type fluorescence immunoassay
procedure was conducted. Incubation times were 1 hour, 30 seconds, and 30 seconds
for capture antibody-antigen reaction, antigen-detection antibody reaction, and detec-
tion antibody-fluorescence labeled antibody reaction, respectively. After the immuno-
assay, fluorescence images were captured by fluorescence microscope and fluorescence
intensity was measured by the fluorescent immunoassay reader. Lung cancer cell lines
harboring ALK or ROS1 fusion (H3122 andHCC78) and lung cancer specimens which
had been obtained at Nagoya University Hospital were used.
Results: To determine the thresholds of fluorescence intensity for ALK and ROS1, we
had used three lung cancer cell lines (H358, HCC827, and H3255) without ALK and
ROS1 fusions. Then, we tested the device for detecting ALK and ROS1 fusions in surgi-
cally resected lung cancer specimens with ALK or ROS1 fusion determined by commer-
cially available methods (Immunohistochemistry for ALK and RT-PCR for ROS1).
Although the number of samples assessed in this experiment was limited, results of the
testing using this device were consistent with those obtained by commercially available
techniques.
Conclusions: These results suggest that our device may be possible candidates for the
next generation diagnostics for ALK and ROS1 fusions.
Legal entity responsible for the study:Nagoya University.
Funding: “Knowledge Hub Aichi”, Priority Research Project from Aichi Prefectural
Government Nagoya University Hospital Funding for Clinical Research Japan Agency
forMedical Research and Development Japan Society for the Promotion of Science.
Disclosure: All authors have declared no conflicts of interest.
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Background: There is no standard therapeutic method for advanced neuroendocrine
carcinoma patients after second line chemotherapy. There is a need for novel effective
therapies for these patients. Apatinib (Hengrui Pharmaceutical Co.,Ltd, Shanghai,
People’s Republic of China) is a novel small molecular vascular endothelial growth fac-
tor receptor-2 (VEGFR-2) inhibitor, which is mainly used to treat stomach and liver
cancers.
Methods:We retrospectively identified the advanced neuroendocrine carcinoma
patients in Bayi Hospital Affiliated Nanjing University of Chinese Medicine Nanjing
who received apatinib therapy for second line or post- second line from August 2015 to
January 2018.The overall survival (OS) was defined as the duration between the date of
treatment initiation to the date of death or last follow-up, with patients alive at last fol-
low up censored on that date. We defined progression-free survival (PFS) from the date
of first recurrence to the date of second recurrence or death, with patients censored on
the date of last follow-up, if the patient was without recurrence on that date. Survival
data was calculated by Kaplan-Meier method. Adverse events were evaluated based on
the National Cancer Institute Common Toxicity Criteria (NCICTC) version 4.0.
Radiographic assessment was made by oncologist and radiologists according to
RECIST1.1.
Results: Ten neuroendocrine carcinoma patients were identified who had received apa-
tinib treatment. The response rate (RR) and disease control rate (DCR) were 10% and
60%, respectively. Median PFS was 8.5 months, and medianOS) was 12.1 months. The
main side effects were proteinuria (30%), oral mucositis (30%), hand-foot syndrome
(30%), and bonemarrow suppression (20%).
Conclusions: Above all, apatinib may provide a novel drug for the treatment of
advanced neuroendocrine carcinoma patients, and also we should pay special attention
to the side effects of apatinb. Meanwhile, further studies are required on the use of apa-
tinib in neuroendocrine carcinoma in order to guide the clinical practice.
Legal entity responsible for the study: The authors.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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